Global Exocrine Pancreatic Insufficiency (EPI) Market — Analysis of Key Trends, Regional Growth, Top Players, and a 10-year Forecast from 2026 to 2036.

Future Market Insights

Exocrine Pancreatic Insufficiency (EPI) Market

Key Insight

Oral is projected to lead route of administration at 91.0% share in 2026, followed by pancreatic enzyme replacement therapy as expected to garner 74.0% share of treatment in 2026. Clinical diagnosis and meal-linked dosing support recurring therapy use, with underdiagnosis and supply interruptions forming principal barriers.

August 04, 2026

Anurag Sharma

250 Pages

Cite this Report

Exocrine Pancreatic Insufficiency (EPI) Market

https://www.futuremarketinsights.com/reports/exocrine-pancreatic-insufficiency-epi-market

License

Buy Now

Summary ToC Infographics Companies

Key Players

Established Oral PERT Providers

AbbVie Inc.
Nestlé Health Science
VIVUS LLC
Digestive Care, Inc.
Nordmark Pharma GmbH

Enteral Enzyme Delivery

Alcresta Therapeutics, Inc.

Emerging Enzyme Development

Anagram Therapeutics, Inc.

Methodology

Member of

Greater New York Chamber of Commerce

Recognized by

Awarded by

SILVER STEVIE® WINNER

Asia Pacific Stevie Awards - 2023

BRONZE STEVIE® Award

20th annual IBAs

Quick Contact

Chat on Whatsapp + 44 20 3769 9709 + 1 347 918 3531 Contact By Email

Get Free Sample PDF

Exocrine Pancreatic Insufficiency (EPI) Market

Key Players

Established Oral PERT Providers

Enteral Enzyme Delivery

Emerging Enzyme Development

Similar Industry Reports